FRI0236 After discontinuation of the 1st tumor necrosis factor inhibitor (TNFI), non-tnfi biologic agents have similar responses but higher survival compared to a 2nd course of a different tnfi: long-term prospective observational study of patients with rheumatoid arthritis in a tertiary hospital of greece

Abstract

BackgroundFor rheumatoid arthritis (RA) patients who discontinue the first biologic agent (bDMARD), most commonly being a TNF inhibitor (TNFi), there is little evidence supporting the next best choice between a...